69097-97-8

Basic information

• Product Name: 7-Hydroxy-2-(p-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-3-one
• Synonyms: 7-Hydroxy-2-(p-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-3-one;7-Hydroxy-2-(p-hydroxyphenyl)chroman-3-one;2,3-Dihydro-7-hydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one;DL-Liquiritigenin;Liquiritigenin Standard
• CAS NO: 69097-97-8
• Molecular Formula: C₁₅H₁₂O₄
• Molecular Weight: 256.25
• Mol File: 69097-97-8.mol
• Article Data: 22

Chemical Properties

• Melting Point: 169-170℃
• Appearance: /
• Density: 1.386
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Acetone (Slightly), DMSO (Slightly, Sonicated), Ethanol (Slightly, Sonicated)
• CAS DataBase Reference: 7-Hydroxy-2-(p-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Hydroxy-2-(p-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-3-one(69097-97-8)
• EPA Substance Registry System: 7-Hydroxy-2-(p-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-3-one(69097-97-8)

Safety Data

• Hazardous Substances Data: 69097-97-8(Hazardous Substances Data)

Usage

Uses

(±)-Liquiritigenin is used in the preparation of liquiritigenin/isoquiritigenin derivative compounds for treatment of cholestatic liver disease.

Upstream product

• 133346-24-4 1-(2,4-dihydroxyphenyl)-3-hydroxy-3-(4'-hydroxyphenyl)-1-propanone 
• 78316-24-2 7,4'-di(methoxymethoxy)flavan-4-one 
• 151-10-0 1,3-Dimethoxybenzene 
• 32568-59-5 4-vinylphenyl benzoate 
• 13745-20-5 2',4,4'-trihydroxychalcone 
• 108-46-3 recorcinol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 128837-26-3 4-(ethyloxymethoxy)benzaldehyde 
• 20034-62-2 2'-Hydroxy-4'-(aethoxy-methoxy)-acetophenon 
• 133346-21-1 Benzoic acid 4-{3-[2,4-bis-(tert-butyl-dimethyl-silanyloxy)-phenyl]-4,5-dihydro-isoxazol-5-yl}-phenyl ester 
• 133346-23-3 5-(4-benzoyloxyphenyl)-3-(2,4-dihydroxyphenyl)isoxazoline 
• 133360-50-6 3-(2,4-dihydroxyphenyl)-5-(4-hydroxyphenyl)isoxazoline 
• 133346-20-0 2,4-di(t-butyldimethylsilyloxy)benzaldehyde oxime 
• 124775-22-0 1-<2-Hydroxy-4-(methoxymethoxy)phenyl>-3-<4-(methoxymethoxy)phenyl>prop-2-en-1-on 

Downstream Products

• 2196-14-7 7,4'-Dihydroxyflavon 
• 78316-26-4 4'-hydroxy-7-O-prenylflavanone 
• 486-66-8 daidzein 
• 109963-62-4 2,7,4'-trihydroxyisoflavanone 
• 485-72-3 7-Hydroxy-3-(4-methoxy-phenyl)-chromen-4-on 
• 486-63-5 isoformononetin 
• 131887-80-4 (2R,3S)-2,7,4'-trihydroxyisoflavanone 
• 24672-86-4 7-hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one 
• 78316-25-3 5,7,3',4’-tetrahydroxy-6,8-di-C-prenylflavanone 
• 78316-27-5 (+/-)-bavachin 
• 101097-68-1 liquiritigenin oxime 
• 59121-64-1 liquiritigenin 7,4′-diacetate 
• 78316-30-0 4'-hydroxy-2,2-dimethylpyrano<5,6:8,7>flavanone 
• 78316-28-6 4'-hydroxy-2,2-dimethylpyrano<5,6:6,7>flavanone 

Relevant articles and documents

Design, synthesis, and cholinesterase inhibition assay of liquiritigenin derivatives as anti-Alzheimer's activity

The marine environment is a rich resource for discovering functional materials, and seaweed is recognized for its potential use in biology and medicine. Liquiritigenin has been isolated and identified from Sargassum pallidum. To find new anti-Alzheimer's activity, we designed and synthesized thirty-two 7-prenyloxy-2,3-dihydroflavanone derivatives (3a-3p) and 5-hydroxy-7-prenyloxy-2,3-dihydro-flavanone derivatives (4a-4p) as cholinesterases inhibitors based on liquiritigenin as the lead compound. Inhibition screening against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) indicated that all synthesized compounds possessed potent AChE inhibitory activity and moderated to weak BuChE inhibitory activity in vitro. Kinetic studies demonstrated that compound 4o inhibited AChE via a dual binding site ability. In addition, all compounds displayed the radical scavenging effects. Finally, the molecular docking simulation of 4o in AChE active site displayed good agreement with the obtained the pharmacological results.

A method of synthesizing the glycyrrhizin (by machine translation)

The invention relates to a synthetic chemical method of glycyrrhizin. In order to 2, 4 - dihydroxy acetophenone and 4 - hydroxy benzoic acid ethyl ester as the raw material, the protective group for a hydroxyl, keto ester condensation, cyclization and hyd

In vitro and in vivo synergistic interaction of substituted chalcone derivatives with norfloxacin against methicillin resistant Staphylococcus aureus

Thirty chalcone derivatives were synthesized via a base catalyzed Claisen Schmidt condensation and evaluated for their anti-methicillin-resistant Staphylococcus aureus (MRSA) activity alone and in combination with norfloxacin. Among these, 5 derivatives namely trans-3-(1H-indol-3-yl)-1-(4′-benzyloxyphenyl)-2-propen-1-one (2), 1-(4″-biphenyl)-3-(3′4′-dihydroxyphenyl)-2-propen-1-one (11), 1-(4″-hydroxy-3″-methylphenyl)3-(4′-hydroxyphenyl)-2-propen-1-one (14), 3-(4′-chlorophenyl)-1-(4″-hydroxyphenyl)2-propen-1-one (17), and LTG-oxime (27) showed significant antibacterial activity with MIC 12.5-50 g mL-1 respectively. In combination studies, derivatives 2 and 14 significantly reduced the MIC of norfloxacin by up to 16 fold (FICI 0.5), while derivatives 11, 17 and 27 reduced it by up to eight fold (FICI ≤ 0.5). Flow cytometry analysis results clearly indicated that derivatives 2 and 14 significantly promote the accumulation and inhibition of the Et-Br efflux, which was further validated through spectrofluorimeter using clinical isolate MRSA-ST2071. In systemically infected Swiss albino mice model, both the compounds significantly (P 0.001, P 0.01) lowered the systemic bacterial load in blood, liver, kidney, lung and spleen tissues. This study supports the promising use of chalcones in the development of economical antibacterial combinations.